• Publications
  • Influence
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
TLDR
Reduction of LDL cholesterol with simvastatin 20 mg plus ezetimibe 10 mg daily safely reduced the incidence of major atherosclerotic events in a wide range of patients with advanced chronic kidney disease. Expand
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
TLDR
In patients undergoing hemodialysis, the initiation of treatment with rosuvastatin lowered the LDL cholesterol level but had no significant effect on the composite primary end point of death from cardiovascular causes, nonf fatal myocardial infarction, or nonfatal stroke. Expand
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial
TLDR
Overall effects of fluvastatin were similar to those of statins in other populations, and seemed to be reduced in cardiac deaths and non-fatal MI, but did not generally reduce rates of coronary intervention procedures or mortality. Expand
Oxidative stress and endothelial function in chronic renal failure.
TLDR
Results show that an impaired endothelium vasodilation function and oxidative stress are related to each other in patients with chronic renal failure. Expand
Impaired endothelium-dependent vasodilatation in renal failure in humans.
TLDR
Patients with moderate CRF have an impaired EDV even after correction for traditional cardiovascular risk factors and this impairment is related to the degree of renal failure, according to this study. Expand
Long‐term Cardiac Outcomes in Renal Transplant Recipients Receiving Fluvastatin: The ALERT Extension Study
TLDR
Fluvastatin produces a safe and effective reduction in LDL‐cholesterol associated with reduced risk of MACE in RTR, and the lipid‐lowering and cardiovascular benefits of fluvastatin are comparable to those of statins in other patient groups, and support use of fluVastatin in R TR. Expand
INDUCTION OF B-TYPE RECEPTORS FOR PLATELET-DERIVED GROWTH FACTOR IN VASCULAR INFLAMMATION: POSSIBLE IMPLICATIONS FOR DEVELOPMENT OF VASCULAR PROLIFERATIVE LESIONS
TLDR
Observations suggest induction of PDGF B-type receptors on vascular smooth muscle cells in inflamed tissues, which would render such cells responsive to growth stimulation by PDGF released from captured platelets, or produced locally (eg, by inflammatory cells or smooth Muscle cells). Expand
Effects of lowering LDL cholesterol on progression of kidney disease.
TLDR
Lowering LDL cholesterol by 1 mmol/L did not slow kidney disease progression within 5 years in a wide range of patients with CKD and showed no significant effect on the rate of change in eGFR. Expand
Serum total homocysteine concentration before and after renal transplantation.
TLDR
The results suggest the post-transplant introduction of one or more factors that induce an increase in tHcy, and treatment with CS appears to be such a factor. Expand
Ischemia causes rapidly progressive nephropathy in the diabetic rat.
TLDR
It is concluded that in diabetic rats renal ischemia causes rapidly progressive kidney damage that in several respects resembles diabetic nephropathy in humans. Expand
...
1
2
3
4
5
...